The Absorption Company's WLP-1 Boosts Natural GLP-1 by Up to 321%
Laura McQuarrie — April 13, 2026 — Lifestyle
References: absorbmore
The Absorption Company, known for its supplements with pharmaceutical-grade absorption, launched WLP-1, an oral GLP-1 biomimetic designed to support the body’s own GLP-1 production. For some, the company's first foray into weight management solutions may be an enticing alternative to injectable weight loss drugs since it avoids prescriptions, needles and the high cost, yet targets the same appetite-regulating hormone pathways.
WLP-1 by The Absorption Company combines clinically studied ingredients to reduce cravings, enhance calorie burn at rest, support healthy weight management, and boost natural GLP-1 by up to 321%. Specifically, three active ingredients are at play in the formula: African mango extract, CQR300 for natural GLP-1 support and fat and carb blocking, and highly absorbed capsaicin.
WLP-1 by The Absorption Company combines clinically studied ingredients to reduce cravings, enhance calorie burn at rest, support healthy weight management, and boost natural GLP-1 by up to 321%. Specifically, three active ingredients are at play in the formula: African mango extract, CQR300 for natural GLP-1 support and fat and carb blocking, and highly absorbed capsaicin.
Trend Themes
1. Oral GLP-1 Biomimetic Supplements - Represents a lower-cost, needle-free alternative to injectable GLP-1 therapies that challenges existing prescription and clinic-based delivery models.
2. Pharmaceutical-grade Supplementation - Signals growing demand for over-the-counter formulations with clinical-grade absorption and measurable efficacy that blur the boundary between supplements and medicines.
3. Plant-based Hormone Modulators - Highlights the potential for botanicals and concentrated extracts to influence appetite-regulating pathways and create scalable, natural ingredient value chains.
Industry Implications
1. Nutraceuticals - Positions supplement companies to capture market share by offering clinically supported, hormone-targeting oral products that compete with traditional drug solutions.
2. Weight Management Clinics - Could shift patient demand away from clinic-administered injectables as more accessible oral alternatives for appetite regulation gain acceptance.
3. Pharmaceuticals and Biotech - Pressures drug developers to pursue non-invasive delivery formats and rethink pricing, regulatory strategies, and competitive positioning around GLP-1 pathways.
6.9
Score
Popularity
Activity
Freshness
